Further subgroup analysis linked grade 3–4 endocrine irAEs with anti-PD-L1 agents in urothelial cancer (OR: 6.23; 95% CI: 2.98–13.1; p < 0.01), as well as with pembrolizumab in NSCLC (OR: 2.78; 95% CI: 0.97–7.31; p = 0.07) and melanoma (OR: 2.06; 95% CI: 1.18–3.73; p = 0.015; Figure S3). The gene discussed is CD274; the disease is melanoma.